- September 30, 2021
Chronic Osteomyelitis in Sacral Pressure Ulcers Management Review in QA Format
Vishal Didwania M.D
Metro Infectious Disease Consultants
Contact Vishal Didwania M.D
You can also search for this author inPubMed | Google Scholar |
Nicholas Van Hise Pharm.D
Metro Infectious Disease Consultants
You can also search for this author inPubMed | Google Scholar |
Kairav Shah M.D
Metro Infectious Disease Consultants
You can also search for this author inPubMed | Google Scholar |
Vishal Didwania M.D
Metro Infectious Disease Consultants
Contact Vishal Didwania M.D
You can also search for this author inPubMed | Google Scholar |
Nicholas Van Hise Pharm.D
Metro Infectious Disease Consultants
Contact Nicholas Van Hise Pharm.D
You can also search for this author inPubMed | Google Scholar |
Kairav Shah M.D
Metro Infectious Disease Consultants
Contact Kairav Shah M.D
You can also search for this author inPubMed | Google Scholar |
How to Cite: Priv. Pract. Infect. Dis., 2021, 1(1): 4; doi: 10.35995/ppid1010002.
© 2021 Copyright by Author. Licensed as an open access article using a CC BY 4.0 license.
METRICS
sacral osteomyelitis; chronic osteomyelitis; decubitus ulcer; sacral wound; antimicrobial stewardship
Key Points
- Most cases of reported osteomyelitis in stage 4 pressure ulcers are almost exclusively chronic and superficial (when depth is reported).
- Wound cultures or bone specimen cultures lack diagnostic sensitivity or specificity. Histopathological diagnosis is necessary to make an accurate diagnosis of osteomyelitis.
- Surgical debridement is the mainstay of treatment for chronic osteomyelitis. Duration of antibiotics in combination with surgical management is unclear but choice should consider bone and biofilm penetration.
- Shorter durations of antibiotics to treat the soft tissue infection should be considered in the absence of a concrete plan for wound coverage with primary closure or rotational flap.
Introduction
Osteomyelitis is, by definition, inflammation of the bone and the bone marrow that can be secondary to bacteria, mycobacteria, or fungi [1]. Defining, diagnosing, and managing chronic osteomyelitis continues to be a challenge for clinicians. Chronic osteomyelitis represents bone infection that is long standing although the exact duration of time before osteomyelitis is considered chronic is unclear. Histological, rather than clinical or imaging based diagnosis is needed. While osteomyelitis can be from hematogenous spread or direct inoculation, in the setting of sacral pressure ulcers, it is commonly from local extension. The most common settings include spinal cord injury or cerebrovascular accident [2]. This is related to local, persistent compression of the area with secondary ischemia. As little as two to six hours of persistent ischemia can lead to cell necrosis and tissue sloughing [3].
- Stage 1: Injury confined to the dermis with lack of tissue necrosis. Once compression is removed the skin is hyperemic and non-blanchable.
- Stage 2: Injury confined to the dermis WITH tissue necrosis. May present as hyperemic area with superficial epidermolysis.
- Stage 3: Injury and necrosis present all the way to the deep fascial layer with lack of exposed muscle, tendon, or bone. May have eschar formation and undermining at wound edges.
- Stage 4: Injury and necrosis breaches deep fascial layers with exposed muscle, tendon, or bone.
Pathogenesis
In order to develop an understanding of a treatment algorithm and a sound approach to management of sacral osteomyelitis, the pathophysiology of osteomyelitis must be understood.
- The pathogenetic sequence can be divided into three major phases. This includes initial microbial invasion, whether exogenously or via a hematogenous route, followed by biofilm proliferation. Biofilm is a matrix of extracellular polymeric substances which provides protection from host defense mechanisms and antibiotics. This is followed by a local immune response to the bacterial biofilm with immunoglobulins and complements leading to activation of polymorphonuclear neutrophils (PMN) as well as production of proinflammatory cytokines. Finally, the bacterial invasion can release virulence factors affecting cell apoptosis, decreased proliferation of osteoblasts, and promotion of osteoclastogenesis. This ultimately leads to destruction of bone tissue [5,6].
- During early biofilm formation the microorganisms are mainly in an aerobic, planktonic state with a high metabolic activity. Once the biofilm is mature, organisms are mainly in an anaerobic state with significantly reduced metabolic activity [6]. They can also hide intracellularly, further limiting access. These properties define the chronicity of infection. Limited in vitro data exist regarding certain antibiotics with activity against bacteria in stationary phase and within biofilms [7].
- S. aureus biofilms secrete soluble molecules which directly impact osteoblasts by decreasing viability and osteogenic potential. S. aureus also secretes protein A (SpA) which is capable of binding to osteoblasts and inhibiting the proliferation and mineralization process. It also induces apoptosis in osteoblasts in vitro [6].
- Human beta-defensins are typically expressed in epithelial and bone tissue that play a key role as antimicrobial peptides and are part of the innate immunity. They are cationic peptides that interact with the anionic membrane of bacteria and encapsulated viral and fungal pathogens, leading to destruction of the cellular membrane and interference with intracellular functions. In extrapolating data from jaw osteomyelitis, Benedicta et al. determined osteomyelitis of the jaw to be a fairly rare event considering it is in a setting of exposed bone after tooth extraction that is exposed to a milieu of oral bacteria. There may be some genetic predisposition or immunosuppressive drug contribution leading to an insufficient immune response. This may lead to an insufficient production of certain beta-defensins. Thus, people on immunosuppressive therapy or with certain genetic predisposition may be more prone to developing chronic osteomyelitis [8].
- Both blood flow and neurological status are key local factors in determining progression to osteomyelitis. Local perfusion arterial networks provide nutrients and oxygen. This can be compromised by direct compression or shear forces that disrupt blood distribution. This combined with neurological insults that would normally allow for change in position to relieve the local pressure in a sensate patient leads to tissue ischemia and focal thrombosis [3].
- Local immune response to pathogens leads to infiltration by leukocytes which release enzymes and pro-inflammatory mediators to destroy the pathogens. This also leads to bone cells and matrix destruction as well as disruption of local blood flow. This results in an avascular area of necrotic, infected bone (sequestrum) and reactive, surrounding formation of new bound involucrum [3].
- Sequestrum is osseous tissue that lacks blood supply and therefore no longer has access to nutrients, to the immune system, or to system antibiotics. This acts essentially as a foreign body and a potential carrier for bacteria and biofilm. Surgical debridement is the only method for eradication [3].
Microbiology
Culture result data from sacral pressure ulcers are challenging to interpret as various methods have been utilized for specimen collection, inconsistent collection of anaerobic cultures, and antibiotic administration prior to culture collection. Additionally, cultures have been obtained from superficial swabs, deep swabs, and bone samples.
- The most common organisms are Staphylococcus aureus, including MRSA, Staphylococcus epidermidis, Streptococcus, Pseudomonas, and enterobacteria as well as anaerobes [3]. Up to 30% of cultures can be polymicrobial [3]. However, even with limited data, most studies have found no association between treatment failure and culture positivity, so the utility of culture directed therapy in the setting of chronic osteomyelitis is unclear. Most of the failures were attributable to patient characteristics, wound management, and lack of source control [5,9,10].
- No, it is expected for bone exposed to the external environment to be colonized with bacteria and a wound swab, superficial or deep, is not sufficient to make a diagnosis of osteomyelitis [3].
- No, cultures of bone specimens are frequently contaminated with organisms residing in adjacent soft tissue [2].
- It is expected for exposed bone to be colonized with bacteria. For this reason, a simple bedside wound swab of a chronic ulcer is not helpful to diagnose the presence of osteomyelitis. Osteomyelitis is an infectious condition characterized by both pathogenic organisms and a corresponding inflammatory or immune response within the bone [3]. When cultures were positive, quantitative bone cultures yielded a similar number of bacterial isolates and a comparable range of bacterial concentration in patients with osteomyelitis vs. those without osteomyelitis [2].
Clinical Findings
Most of the data support a histologic diagnosis of osteomyelitis. In some cases, it may not be feasible to obtain a biopsy specimen for histology and culture. Again, the data is limited on the ability of clinical findings to make an accurate diagnosis but fairly consistent.
- Traditionally, it was thought that exposed bone defined osteomyelitis but as discussed above both pathogen and histologic examinations are required for the diagnosis [3]. This is important when assessing various studies as the study definition of osteomyelitis impacts the prevalence of osteomyelitis in its patient population.
- Turk et al. [12] used four distinct categories in autopsy patients with stage 4 sacral pressure ulcers.
- Full-thickness soft-tissue disease without osseous involvement (seven patients);
- Increased osteoclastic activity and reactive bone formation with inflammatory cells (seven patients);
- Fibrotic osseous involvement without evidence of osteomyelitis (one patient);
- Osteomyelitis (13 patients).
- Even in patients defined as having osteomyelitis, only half had cortical involvement with chronic osteomyelitis and the rest with small foci of acute on chronic osteomyelitis without extensive bone destruction. If the cases of superficial chronic osteomyelitis are excluded, then even fewer cases remain and the location of osteomyelitis in those cases were focal and are not diffuse or extensive.
Lab Findings
Most patients being managed for chronic osteomyelitis in the inpatient or outpatient setting at one time or another have received typical blood tests, including inflammatory markers to assist in the diagnosis of osteomyelitis. Even though most data suggest poor correlation of many of these tests with chronic osteomyelitis, they are still frequently ordered.
- The most common tests include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and alpha-1 acid glycoprotein [5]. They are usually elevated but have low sensitivity and specificity. They may be helpful to assist in early diagnosis of postoperative bone infection and to assess the effectiveness of antibiotics during the course of antibiotic therapy [5].
- Most of the studies have shown histologically confirmed chronic osteomyelitis as typically being superficial or focal without deep or diffuse involvement [3]. On histology mild infiltrates of lymphocytes and plasma cells were seen involving mostly the superficial bone. Acute inflammatory cells were not observed in bone and tissue stains did not show any bacteria. Osteomyelitis was always associated with pressure-related changes, including the presence of encasing fibrotic tissue with some degree of chronic inflammation and reactive bone formation [2].
Imaging
There has been much discussion regarding the role of imaging in the diagnosis of osteomyelitis including radiographs, computed tomography (CT), magnetic resonance imaging (MRI), and scintigraphy. The challenge is differentiating via imaging the reactive bony changes from true infection.
- Many studies reference Larson et al. [13], who showed a combined sensitivity of plain film and CT to be only 61% and specificity of 69%. However, osteomyelitis was defined based on positive bone culture rather than histopathology. Additionally, radiologic studies up to 1 year prior to surgery were included. However, Lewis et al. [14] showed, among 52 patients, the sensitivity and specificity of plain films and CT was 18% and 100% and 11% and 90%, respectively, compared to bone biopsy at surgical debridement. Histopathologic osteomyelitis was defined as both osteonecrosis and inflammatory infiltration of the bone.
- Daniali et al. compared 26 patients with MRI diagnosed osteomyelitis to 21 patients with osteomyelitis diagnosed by intraoperative bone culture positivity. Osteomyelitis diagnosed via MRI compared to culture growth from an intraoperative specimen found no difference in surgical technique, perioperative management, or patient outcomes [16].
- Most of the data regarding true sensitivity and specificity of imaging techniques are poor with small sample sizes and comparison to bone culture rather than histopathology. There does not seem to be a clear or proven benefit to obtaining any radiographs strictly for the diagnosis of chronic osteomyelitis in a sacral pressure ulcer. Logically, even if an imaging test revealed true osteomyelitis, antibiotics would not be initiated simply based on this result. Surgical management would have to be pursued including debridement, revascularization, and wound coverage at which time a reliable diagnosis can be made via bone biopsy and histopathology [3,13,16].
Management
Management of chronic osteomyelitis has been a challenge for decades related to accurate diagnosis, sufficient debridement, and proper revascularization with removal of dead space and coverage. Even when all this has been achieved, there exists issues related to nutritional status, BMI, smoking status, and insufficient offloading. Antibiotics have a role in management in conjunction with above and not as an isolated therapy.
Antibiotics
What is the recommended duration of treatment for chronic osteomyelitis?
- The traditional recommendation of 4–6 weeks of parenteral antibiotics is based on data from the 1970s and the idea that it takes 3–4 weeks for infected bone to revascularize [17]. Otherwise, data on this topic are very limited and most studies do not show clear benefits between duration of antibiotic treatment and impact on risk of ulcer recurrence [3]. There is no clear indication for antibiotic treatment without plans for definitive wound coverage [3].
- A Cochrane study published in 2013 that included pooled results from 150 participants did not show any difference in terms of the number of people who did not have symptoms at the end of treatment. Additionally, it did not show any difference in the number of people who had negative side effects or had a superinfection. These data suggest that the route of antibiotic administration does not impact disease remission if the bacteria causing the infection are sensitive to the antibiotic used. However, many of these trials are greater than twenty years old and the prevalence of resistant bacteria is greater now [1].
- Fluoroquinolones, sulfamides, cyclines, macrolides, rifamycins, and oxazolidinones [17,18]. These classes of antibiotics also have the highest bioavailability. A table of pathogen specific antibiotics including route of administration, dose, and frequency can be found in the work of Fantoni et al. [18].
- There is insufficient data regarding optimal duration of therapy or best antibiotic choice. However, after sufficient surgical debridement to remove any necrotic bone and flap closure to restore sufficient vascular supply and remove dead space, the antibiotics can be tailored based on the bone cultures obtained at the time of surgery [3].
- Marriott et al. discussed patients that received the above therapy with pathology negative for acute osteomyelitis; they were treated for 5–7 days with intravenous antibiotics [10]. Patients treated with this shorter duration of antibiotics showed no difference in duration of postoperative hospitalization, rate of ulcer recurrence, or rate of subsequent wound breakdown when comparing patients with chronic osteomyelitis and the negative osteomyelitis group.
- Wong et al. [5] reviewed multiple additional studies which found no significant difference in infection recurrence and duration of antibiotics.
- Since biofilms can allow for relapses of chronic osteomyelitis, some experts suggest the use of an antibiotic (e.g., rifampin) with activity against microorganisms in biofilm as a combination drug in both parenteral and oral regimens [5]. Other agents include lipoglycopeptides, which kill S. aureus in the stationary phase and within biofilms [7,19]. These agents have allowed us to stop the combination treatment with rifampin and use only monotherapy.
- In general, there is no role for empiric antibiotics without definitive plans for debridement and wound coverage. Parenteral beta lactams, however, have always been one of the mainstays of therapies as they provide high serum concentrations along with adequate bone and tissue penetration into the site of infection. Other options include the once-weekly lipo-glycopeptides which carry the added benefit of additional biofilm penetration. These are only to be used empirically in combination with a Gram-negative therapy agent until cultures have been obtained. It is good to remember though that two-thirds of all chronic osteomyelitis cases are caused by Staphylococcus aureus [7].
Surgical
Does presence of osteomyelitis prior to flap coverage lead to higher complication rates?
- No, positive bone culture from a biopsy was not correlated with increased recurrence or complications. It would be reasonable to proceed with surgery for debridement and flap coverage without first delaying treatment with antibiotics. If cultures are positive, then appropriate antibiotics can be used for treatment in combination with surgical treatment [9].
- Larson et al. concluded that “placing a patient on a prolonged course of antibiotics empirically, or guided by a diagnostic culture, without providing coverage over that bone is illogical and a waste of resources, as the bone is still open and susceptible to recurrent infection” [9].
- Bejany et al. discussed four patients with paraplegia and pressure ulcers who had failed previous attempts at ulcer healing with muscular flaps and a suprapubic catheter. After undergoing a diverting colostomy for stool and a Miami pouch for urinary diversion, all four patients achieved ulcer healing [21]. Additionally, de la Fuente compared colostomy vs. non-colostomy with the majority of colostomies performed laparoscopically. The findings showed lower ulcer recurrent rate in colostomy group as well as a shorter healing time [22].
Recurrence and Complications
Recurrence seems to be a frequent problem reported at >50% in multiple studies [20,23], so understanding risk factors that can lead to an increased rate of recurrence would help in optimizing management and cost savings.
- In the data of Bamba et al., looking at 276 patients the risk factors associated with recurrence included: BMI < 18.5 kg/m2, active smoking, low preoperative albumin [3,24]. Additionally, persistence of initial patient characteristics that led to the ulcer formation, including inability to offload pressure.
- Based on limited data of Jugun et al., most of the cases of recurrences were with a different bacteria compared to the original infection, suggesting a new problem rather than a failure of the initial management [23].
- Based on a retrospective study by Larson et al. looking at 101 patients with 179 pressure ulcers, there was no association found between positive bone cultures and recurrence or complications [9].
Summary
Based on the review of available data, it is clear that more research on this topic is necessary, especially randomized controlled trials. Additionally, much of the data are decades old with a limited sample size and variable definitions of osteomyelitis. What seems clear, however, is a single pronged strategy based on administration of prolonged antibiotics is likely to lead to treatment failure. A multipronged approach including treating the underlying cause of the pressure ulcer is most likely to be successful.
- Conterno, L.; Turchi, M.D. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst. Rev. 2013, CD004439. [Google Scholar] [CrossRef]
- Darouiche, R.; Landon, G.C.; Klima, M.; Musher, D.M.; Markowski, J. Osteomyelitis associated with pressure sores. Arch. Intern. Med. 1994, 154, 753–758. [Google Scholar] [CrossRef] [PubMed]
- Crespo, A.; Stevens, N.M.; Chiu, E.; Pham, V.; Leucht, P. Incidence of Osteomyelitis in Sacral Decubitus Ulcers and Recommendations for Management. JBJS Rev. 2020, 8, e0187. [Google Scholar] [CrossRef]
- Edsberg, L.E.; Black, J.M.; Goldberg, M.; McNichol, L.; Moore, L.; Sieggreen, M. Revised National Pressure Ulcer Advisory Panel Pressure Injury Staging System: Revised Pressure Injury Staging System. J. Wound Ostomy Cont. Nurs. 2016, 43, 585–597. [Google Scholar] [CrossRef]
- Wong, D.; Holtom, P.; Spellberg, B. Osteomyelitis Complicating Sacral Pressure Ulcers: Whether or Not to Treat With Antibiotic Therapy. Clin. Infect. Dis. 2019, 68, 338–342. [Google Scholar] [CrossRef]
- Beck-Broichsitter, B.E.; Smeets, R.; Heiland, M. Current concepts in pathogenesis of acute and chronic osteomyelitis. Curr. Opin. Infect. Dis. 2015, 28, 240–245. [Google Scholar] [CrossRef] [PubMed]
- Chastain, D.B.; Davis, A. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. Int. J. Antimicrob. Agents 2019, 53, 429–434. [Google Scholar] [CrossRef] [PubMed]
- Beck-Broichsitter, B.E.; Dau, H.; Moest, T.; Jochens, A.; Stockmann, P.; Wiltfang, J.; Becker, S.T. Immunohistological expression of human ß-defensin-1 and human ß-defensin-2 in exacerbation of acute and secondary chronic osteomyelitis of the mandible. J. Oral Pathol. Med. 2015, 44, 88–93. [Google Scholar] [CrossRef]
- Larson, D.L.; Hudak, K.A.; Waring, W.P.; Orr, M.R.; Simonelic, K. Protocol management of late-stage pressure ulcers: A 5-year retrospective study of 101 consecutive patients with 179 ulcers. Plast. Reconstr. Surg. 2012, 129, 897–904. [Google Scholar] [CrossRef] [PubMed]
- Marriott, R.; Rubayi, S. Successful Truncated Osteomyelitis Treatment for Chronic Osteomyelitis Secondary to Pressure Ulcers in Spinal Cord Injury Patients. Ann. Plast. Surg. 2008, 61, 425–429. [Google Scholar] [CrossRef]
- Sugarman, B.; Hawes, S.; Musher, D.M.; Klima, M.; Young, E.J.; Pircher, F. Osteomyelitis Beneath Pressure Sores. Arch. Intern. Med. 1983, 143, 683–688. [Google Scholar] [CrossRef]
- Türk, E.E.; Tsokos, M.; Delling, G. Autopsy-Based Assessment of Extent and Type of Osteomyelitis in Advanced-Grade Sacral Decubitus Ulcers: A Histopathologic Study. Arch. Pathol. Lab. Med. 2003, 127, 1599–1602. [Google Scholar] [CrossRef]
- Larson, D.L.; Gilstrap, J.; Simonelic, K.; Carrera, G.F. Is There a Simple, Definitive, and Cost-Effective Way to Diagnose Osteomyelitis in the Pressure Ulcer Patient? Plast. Reconstr. Surg. 2011, 127, 670–676. [Google Scholar] [CrossRef] [PubMed]
- Lewis, V.L.; Bailey, M.H.; Pulawski, G.; Kind, G.; Bashioum, R.W.; Hendrix, R.W. The Diagnosis of Osteomyelitis in Patients with Pressure Sores. Plast. Reconstr. Surg. 1988, 81, 229–232. [Google Scholar] [CrossRef]
- Brunel, A.-S.; Lamy, B.; Cyteval, C.; Perrochia, H.; Téot, L.; Masson, R.; Bertet, H.; Bourdon, A.; Morquin, D.; Reynes, J.; et al. Diagnosing pelvic osteomyelitis beneath pressure ulcers in spinal cord injured patients: a prospective study. Clin. Microbiol. Infect. 2016, 22, 267.e1–267.e8. [Google Scholar] [CrossRef]
- Daniali, L.N.; Keys, K.; Katz, D.; Mathes, D. Effect of Preoperative Magnetic Resonance Imaging Diagnosis of Osteomyelitis on the Surgical Management and Outcomes of Pressure Ulcers. Ann. Plast. Surg. 2011, 67, 520–525. [Google Scholar] [CrossRef] [PubMed]
- Spellberg, B.; Lipsky, B.A. Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults. Clin. Infect. Dis. 2011, 54, 393–407. [Google Scholar] [CrossRef] [PubMed]
- Fantoni, M.; Taccari, F.; Giovannenze, F. Systemic antibiotic treatment of chronic osteomyelitis in adults. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 258–270. [Google Scholar] [PubMed]
- Van Hise, N.W.; Chundi, V.; Didwania, V.; Anderson, M.; McKinsey, D.; Roig, I.; Sharma, A.; Petrak, R.M. Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study. Drugs Real World Outcomes 2020, 7, 41–45. [Google Scholar] [CrossRef]
- Goodman, C.M.; Cohen, V.; Armenta, A.; Thornby, J.; Netscher, D.T. Evaluation of Results and Treatment Variables for Pressure Ulcers in 48 Veteran Spinal Cord-Injured Patients. Ann. Plast. Surg. 1999, 42, 665–672. [Google Scholar] [CrossRef] [PubMed]
- E Bejany, D.; Chao, R.; E Perito, P.; A Politano, V. Continent urinary diversion and diverting colostomy in the therapy of non-healing pressure sores in paraplegic patients. Spinal Cord 1993, 31, 242–248. [Google Scholar] [CrossRef]
- De La Fuente, S.G.; Levin, S.L.; Reynolds, J.D.; Olivares, C.; Pappas, T.; Ludwig, K.A.; Mantyh, C.R. Elective Stoma Construction Improves Outcomes in Medically Intractable Pressure Ulcers. Dis. Colon Rectum 2003, 46, 1525–1530. [Google Scholar] [CrossRef] [PubMed]
- Jugun, K.; Richard, J.-C.; Lipsky, B.A.; Kressmann, B.; Pittet-Cuenod, B.; Suvà, D.; Modarressi, A.; Uçkay, I. Factors Associated With Treatment Failure of Infected Pressure Sores. Ann. Surg. 2016, 264, 399–403. [Google Scholar] [CrossRef] [PubMed]
- Bamba, R.; Madden, J.J.; Hoffman, A.N.; Kim, J.S.; Thayer, W.P.; Nanney, L.B.; Spear, M.E. Flap Reconstruction for Pressure Ulcers. Plast. Reconstr. Surg. Glob. Open 2017, 5, e1187. [Google Scholar] [CrossRef] [PubMed]